ANGPTL6 antibody
- Known as:
- ANGPTL6 (anti-)
- Catalog number:
- orb101541
- Product Quantity:
- EUR
- Category:
- -
- Supplier:
- Biorbyt biorb
- Gene target:
- ANGPTL6 antibody
Related genes to: ANGPTL6 antibody
- Gene:
- ANGPTL6 NIH gene
- Name:
- angiopoietin like 6
- Previous symbol:
- -
- Synonyms:
- ARP5, AGF
- Chromosome:
- 19p13.2
- Locus Type:
- gene with protein product
- Date approved:
- 2003-09-24
- Date modifiied:
- 2018-05-24
Related products to: ANGPTL6 antibody
Related articles to: ANGPTL6 antibody
- Liver fibrosis, characterized by excessive extracellular matrix deposition, is a critical stage in chronic liver disease progression. Angiopoietin-like protein 6 (ANGPTL6), a hepatocyte-secreted protein involved in metabolism, has an unclear role in fibrosis. This study investigated ANGPTL6's function in hepatic fibrosis, focusing on its suppression of hepatic stellate cells (HSCs) activation via the transforming growth factor-beta 1/Smad3 (TGF-β1/Smad3) pathway. Mouse models of metabolic dysfunction-associated steatohepatitis (MASH) and fibrosis were established using a methionine-choline deficient diet (MCD). Adeno-associated virus serotype 8 (AAV8) was used to overexpress ANGPTL6 in vivo, with TGF-beta receptor 2 (TGFBR2) co-overexpression for rescue studies. In human HSCs (LX-2 cells), gain- and loss-of-function experiments were performed. Fibrosis was assessed via histology, immunohistochemistry, western blot, and quantitative real-time polymerase chain reaction (qRT-PCR). ANGPTL6 was downregulated in fibrotic livers. Consistently, its overexpression attenuated MCD-induced liver damage, reducing serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels, inflammation, and fibrosis markers. TGFBR2 co-expression reversed this protection, restoring TGF-β1/Smad3 activation. In LX-2 cells, ANGPTL6 suppressed TGF-β1-induced HSCs activation, an effect eliminated by TGFBR2 plasmid transfection but enhanced by TGFBR2 inhibition. These findings identify ANGPTL6 as an endogenous suppressor of HSCs activation through TGF-β1/Smad3 inhibition, highlighting its therapeutic potential for fibrotic liver diseases like MASH. - Source: PubMed
Publication date: 2026/03/19
Tang XiaoqianWen ShengcongZhang JunLi BaiDong ZhenyaZhang QiangZhang TingWang YangZhu JinglingZhang Yunhua - Chronic Hepatitis C Virus (HCV) infection is associated with systemic metabolic disturbances, including glucose intolerance, lipid dysregulation, and inflammation, accelerating liver fibrosis and increasing hepatocellular carcinoma risk. Biomarkers such as Glucagon-Like Peptide-1 (GLP-1), Fatty Acid-Binding Protein 1 (FABP-1), Monocyte Chemoattractant Protein-1 (MCP-1), Angiopoietin-Like Protein 6 (ANGPTL6), ibroblast Growth Factor 19 (FGF-19), and ghrelin offer insights into these mechanisms and may reflect the impact of antiviral treatments. - Source: PubMed
Publication date: 2026/02/25
Jędrysik MalwinaTomasiewicz KrzysztofChełstowska BeataTudrujek-Zdunek MagdalenaSzymański Filip M - Fetal growth restriction (FGR) is a major contributor to perinatal morbidity and mortality, most commonly arising from placental dysfunction, with increasing evidence implicating aberrant DNA methylation in its pathogenesis. To identify robust epigenetic alterations associated with FGR, we analyzed placental chorionic villi from an in-house early-onset FGR cohort and compared them with a publicly available dataset (GSE100197). DNA methylation profiling was performed using Illumina EPIC (in-house) and 450K (public) arrays, processed with identical normalization and quality-control pipelines, including adjustment for gestational age and estimation of placental cell-type composition. Differentially methylated positions (DMPs) were identified using linear regression models, revealing 10,427 DMPs in the in-house cohort and 7467 in the public dataset, with 108 shared DMPs showing consistent direction of change across both cohorts. Promoter-associated DMPs were mapped to genes involved in angiogenesis, morphogenesis, immune regulation, and transcriptional control, including , , , , and , while additional novel candidates such as , , and family members were also identified. Functional annotation suggests that these methylation changes may influence pathways essential for placental vascular development and structural organization. Overall, this cross-cohort comparison highlights reproducible epigenetic signatures of FGR and underscores the need for standardized approaches to clarify the molecular mechanisms underlying placental insufficiency. - Source: PubMed
Publication date: 2026/01/31
Bednarek-Jędrzejek MagdalenaTaryma-Leśniak OlgaPoniatowska MałgorzataCejko MateuszMaksym KatarzynaDzidek SylwiaBlatkiewicz MałgorzataKwiatkowska EwaTorbé AndrzejKwiatkowski Sebastian - Multiple myeloma (MM) is the second most common blood malignancy, with several lines of evidence supporting an inherited genetic component. Here, we sequenced 177 affected individuals from 128 families, and 170 early-onset MM cases diagnosed before 55 years of age. Samples were identified and collected through nationwide efforts in France, Sweden, and Greece. We focused on rare germline protein truncating and likely deleterious missense variants in genes harboring variants in at least two families showing variant-disease segregation, and in additional index (≥2) and/or early-onset (≥2) cases. We identified likely pathogenic variants in ATM (N = 12), ANGPTL6 (N = 5), and FBXW9 (N = 6). Additionally, we detected variants in previously reported MM predisposition genes, including DIS3, EP300, and KDM1A. Our results represent the largest sequencing study on familial and early-onset MM to date, and further illuminate the constitutional genetic basis of MM. - Source: PubMed
Publication date: 2025/11/18
Pertesi MaroulioDemangel DelphineNiroula AbhishekPerrial EmelineMahecha Escobar Maria LauraVallée MaximeLiacos ChristineSamur Mehmet KSperling Adam SMunshi Nikhil CKastritis EfstathiosDimopoulos Meletios AMcKay James DMellqvist Ulf-HenrikHansson MarkusDumontet Charles Nilsson Björn - This study explores the therapeutic potential and mechanisms of Modified Danggui Buxue Decoction (MDBD) in diabetic retinopathy (DR) using network pharmacology, bioinformatics, machine learning, Mendelian randomization (MR), molecular docking, and experiments. - Source: PubMed
Publication date: 2025/10/10
Poon Lee YamHsu Li MeiLam Lai KwanHuang XiaoqingXu PengliLiang QiuerXie PengchengYang Shuyu